The Food and Drug Administration has given companies, scientists and members of the public an additional month to submit data on butylated hydroxytoluene, a preservative that appears on the ingredient labels of breakfast cereals, frozen meals, baking mixes, cookies and chewing gum. The new deadline is August 31, 2026.
The reopening, published in the Federal Register on July 30, restarts a comment window that had already closed on July 13. For shoppers, nothing changes at the grocery store today. BHT remains legal in food, and the FDA has not issued a warning, a restriction or a finding of harm. What has changed is that the agency's evidence-gathering file on the chemical is open again, and the record it collects now will shape whatever the FDA decides later.
That distinction matters because reassessment notices are easily misread. A federal agency asking for safety data is not the same as a federal agency announcing a problem.
The Reopening, in Plain Terms
The FDA opened a 60-day request for information on BHT on May 13, 2026, asking for current use levels and safety data on the chemical in human food and in food packaging. That window ran through July 13.
After the notice published, the agency received a request for more time. According to the Federal Register notice, the request argued that 60 days was "insufficient to allow impacted stakeholders to develop a complete and scientifically robust submission," citing the time needed for supply chain communications. Because the request arrived too late for a standard extension, the FDA reopened the period instead, adding 30 days.
Comments go to Docket No. FDA-2026-N-2526 through Regulations.gov, and electronic submissions will be accepted until 11:59 p.m. Eastern time on August 31. Written comments may also be mailed to the agency's Dockets Management Staff in Rockville, Maryland. Submissions are posted publicly, so the FDA warns commenters not to include personal or confidential business information unless they file it under the separate confidential-submission process.
One parallel review did not get extra time. The FDA issued a matching request for information on azodicarbonamide, a dough conditioner and bleaching agent used in baked goods, on the same day in May. The agency said it received no stakeholder requests for additional time on that docket, and the azodicarbonamide record closed on schedule July 13.
A Preservative with a Long Regulatory History
BHT is an antioxidant. Its function is to slow the chemical breakdown of fats and oils, which is what produces rancid flavors and off smells in packaged food. It is also used as an antioxidant in materials that touch food, meaning packaging as well as the food itself.
The chemical has been authorized in the United States for decades. Federal regulation at 21 CFR 172.115 permits BHT alone or combined with the related preservative BHA in specified foods at set limits measured in parts per million, including dry breakfast cereals, potato flakes and dehydrated potato shreds. Any use of BHT in food must be covered by a food additive regulation, an effective food contact notification, or an exclusion such as generally recognized as safe status.
Consumer concern about BHT is not new either, and it has produced a research literature that points in more than one direction. Health Canada notes that people are also exposed to BHT through drinking water, cosmetics, plastics and other consumer products, not food alone. Because BHT reaches people through several routes at once, total exposure is one of the harder questions in any reassessment.
Reassessment Is Not a Safety Verdict
This is the single most important thing for readers to understand about the July 30 notice.
The FDA said in its original request that it intends to use the information it receives to determine whether BHT "remains safe under its current conditions of use" in food and in food contact materials. That is the language of an open question, not a conclusion. The agency has not proposed a rule, has not restricted any use, and has not stated that current exposure levels present a risk.
BHT and azodicarbonamide are the first two chemicals selected under a post-market assessment program the FDA finalized in May 2026, a framework for systematically re-examining substances already in the food supply, including generally recognized as safe substances, food additives, color additives and food contact substances. Announcing the program, then-Commissioner Marty Makary said Americans want the agency to "take a fresh look at some of the chemical additives" that have become common in food.
Selection for review reflects prioritization, not a finding. A chemical can be chosen because it is widely used, because the underlying safety data are old, or because newer science exists, and none of those reasons presupposes an outcome.
Shoppers, Label Readers and the Practical Takeaway
For most households, this notice calls for no action at all. There is no recall, no product to check and no lot code to look up.
The people with a concrete reason to act in August are those with information to contribute: food manufacturers and packaging suppliers who know actual use levels, toxicologists and academic researchers with relevant data, consumer and public health organizations, and members of the public who want their views in the record. The docket is open to anyone, and comments filed after the deadline will not be considered.
Readers who prefer to limit BHT in the meantime can do what they could already do, which is read ingredient panels. BHT is listed by name, and many products in the categories where it is common are also sold in formulations without it. That is a personal preference decision rather than a response to any official guidance, because official guidance has not changed.
Anyone with a specific medical concern about food additives, particularly parents of children with existing sensitivities, should raise it with a clinician who knows the child's history rather than acting on a regulatory notice.
Next Steps in the Docket
After August 31, the FDA will review what it received and continue its post-market assessment. The agency has not announced a target date for completing the BHT review or committed to a specific next action.
Several outcomes are possible. The FDA could conclude that current uses remain safe and take no action. It could propose changes to permitted uses or limits, which would require its own rulemaking with a separate public comment period. It could seek additional information. The azodicarbonamide assessment continues on its closed record and may reach its own conclusion on a different timeline.
The immediate confirmed fact is narrow and worth stating plainly: the comment period reopened, and it closes August 31. The most affected audience is industry and the research community, not shoppers. The central uncertainty is what the assembled evidence will show, and no one, including the FDA, can answer that until the record is complete. MedicalDaily will monitor Docket No. FDA-2026-N-2526 for the agency's next action.
Frequently Asked Questions
Did the FDA find that BHT is unsafe?
No. The agency is gathering information to determine whether BHT remains safe under its current conditions of use. It has made no finding of harm and taken no enforcement action.
Is there a recall on any product containing BHT?
No. There is no recall, no public health alert and no product to check.
Where is BHT typically found?
It is used as an antioxidant to prevent fats and oils from spoiling. It appears in products such as dry breakfast cereals, frozen meals, baking mixes, cookies, chewing gum and some meat products, and in materials that contact food.
Why did the FDA reopen a comment period that had already closed?
Stakeholders asked for more time, arguing that 60 days was not enough to assemble complete data. Because the request came in after the original deadline, the agency reopened the window for 30 days rather than extending it.
Who can submit a comment, and how?
Anyone. Electronic comments go to Regulations.gov under Docket No. FDA-2026-N-2526 until 11:59 p.m. Eastern on August 31, 2026. Written comments may be mailed to the FDA's Dockets Management Staff.
Should I stop buying products that list BHT?
Current federal guidance has not changed, and there is no official recommendation to avoid BHT. Readers who prefer to limit it can check ingredient labels, which is a personal preference rather than a response to a safety warning.
What happens after the deadline?
The FDA reviews the submissions as part of its post-market assessment. Any change to permitted uses would require separate rulemaking with its own comment period. No completion date has been announced.
